India Multiple Myeloma Market Analysis Sample Report

India Multiple
Myeloma Market
Analysis
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of India Multiple Myeloma
Market and a forecast for its development in the medium and long term. It
provides a comprehensive overview of the market value, dynamics,
segmentation, characteristics, main players, trends and insights, growth
and demand drivers, challenges & future outlook, etc. This is one of the
most comprehensive reports about the India Multiple Myeloma Market,
and offers unmatched value, accuracy, and expert insights

Table of
Contents
• Market Overview
• Growth Drivers & Restraints
• Market Segmentation
• Major Market Share
• Competitive Landscape
• Key Company Profiles
• Healthcare Policies & Regulatory Framework
• Factors Driving Future Growth
• Future Opportunities
• Conclusion

4 A Sample Report on Indian Multiple Myeloma Market I Confidential
Table of Contents
1. India Multiple Myeloma Market Overview……………………………………………...………………………………………………………….08
1.1 Market size and forecast
2. Market growth drivers and restraints …………………………………………………………………….…………………………………………10
2.1 Market Growth Drivers
2.1.1 Increasing prevalence of hematological cancer
2.1.2 Introduction of monoclonal antibodies
2.1.3 Increasing investment for healthcare infrastructure
2.2 Market Restraints
2.2.1 High cost associated with the treatment
2.2.2 Lack of skilled professionals and healthcare infrastructure
3. Disease Epidemiology…………….…………….………………………………………………….…………..……………………….……........….16
3.1 Incidence rate
3.2 Prevalence rate

Table of Contents (continued)
4. Multiple myeloma market segmentation…………………………………….………………………………....…………………………........….19
4.1 By disease type
4.2 By treatment type
4.3 By diagnosis type
4.4 By dosage forms
4.5 By route of administration
4.6 By end users
4.7 By distribution channel
5. Multiple myeloma major products market share…………………………………………………………………………...………..……………28
5.1 Market analysis, insights and forecast - By revenue
6. Competitive Landscape…………………………………………………………………………………………………….……………………...….30
6.1 Major players

Table of Contents (continued)
7. Key Company Profiles (Company Overview, Product & Services, Strategies & Financials) ….…………………………...……………........33
7.1 Zydus Pharmaceuticals
7.2 Dr. Reddy's Laboratories
7.3 Ciplamed
7.4 Sun Pharma
7.5 Biocon Biologics India Limited
8. Healthcare policies and regulatory landscape………………………………….……………………………………………...…………………44
8.1 Policy changes and Reimbursement scenario
9. Factors driving future growth…………………………………………………………………………………………….…………………...……..46
9.1 Future opportunities
10. Strategic recommendations…………………………………………………………………………………………………..………….……..…..48

“Multiple myeloma (MM) is an incurable disease with
relapsing-remitting nature. Managing a patient with MM in
India has several constraints, including the availability of
infrastructure (equipment, expertise, and quality
assurance), reluctance to avail autologous stem-cell
transplant (ASCT), frequent change of health care
facilities. Hence there is huge demand for multiple
myeloma treatment in the country”

India Multiple Myeloma Market Analysis
1. Overview

(Current and Forecast)
▪ India Multiple Myeloma market size stood at around $XX Bn in
2022 and is projected to reach $XX Bn by 2030, exhibiting a
CAGR of xx% during the forecast period
▪ The worldwide Age Standardized Rate (ASR) for the incidence of
multiple myeloma as per the GLOBOCAN/IARC data is
1.4/1,00,000 population accounting for 1,00,000 new cases every
year
▪ In India it accounts for around 5,900 deaths every year. The USA
SEER data shows that the Age-Adjusted Death Rate was
3.4/1,00,000 population
▪ Hence, in recent years, the Indian multiple myeloma market is
anticipated to grow rapidly
Key Analysis

2. Growth Drivers and Growth Restraints

Market Growth Drivers and Restrains
Increasing prevalence of
hematological cancer
Introduction of monoclonal
antibodies
High cost associated with the
treatment
Increasing investment for
healthcare infrastructure
Lack of skilled professionals and

2.1 Market Growth Drivers
The rising prevalence of hematological cancer is estimated to enhance the multiple myeloma market's growth rate.
Multiple myeloma is a form of hematological cancer triggered by certain genetic defects The disease is treated with
medications that modify the immune system and improve the efficacy of chemotherapies, radiation therapies, stem
cell transplants, and platelet transfusions
Sample
2.1.1 Increasing prevalence of hematological cancer
Sample

Market Growth Drivers (continued)
2.1.2 Introduction of monoclonal antibodies with safety profile to fight myeloma cells
The expansion of the multiple myeloma market is fueled by the increasing use of microRNA treatments, the rise of
nanomedicine platforms, and the constant introduction of effective and safe therapeutics
With the addition of monoclonal antibodies and histone deacetylase (HDAC) inhibitors to the present therapies array,
the medicines market is likely to gain traction. Because of the established clinical profile, clinicians favor biologic
therapy with monoclonal antibodies such as darzalex and empliciti
Sample

Market Growth Drivers (continued)
2.1.3 Increasing investment for healthcare infrastructure
Significant factor influencing the growth rate of multiple myeloma market is the rising healthcare expenditure which
helps in improving its infrastructure
Rising investment for the development of advanced technologies and increase in the number of emerging markets
will further provide beneficial opportunities for the multiple myeloma market growth during the forecast period
Sample

2.2 Market Restraints
Sample
▪ In India treatment rates are low because of the high
cost associated with the treatment of multiple
myeloma will obstruct the market's growth rate
2.2.1 High cost associated with the treatment
Sample
▪ The dearth of skilled professionals and lack of
healthcare infrastructure in developing economies
will challenge the multiple myeloma market.
2.2.2 Lack of skilled professionals and

3. Epidemiology of Multiple Myeloma

17
3.1 Incidence rate of multiple myeloma in India
▪ The worldwide Age Standardized Rate (ASR) for incidence of multiple myeloma as per the GLOBOCAN/IARC data is 1.4/1,00,000
population accounting to 1,00,000 new cases every year
▪ The incidence rate of multiple myeloma in India is 0.7/1,00,000 population amounting to about 6,800 new cases a year
▪ The incidence of multiple myeloma increases with age. More than 75% cases occurring between the age group of 55- 85 years. There are
only few cases reported below 20 years of age
▪ Multiple myeloma comprised 11.1% of all hematological malignancies. 80-90% myeloma patient have myeloma bone disease. This figure
is higher in Indian patients given the facts that Vitamin D deficiency and post-menopausal osteoporosis incidences are higher in Indian
population
▪ Content
▪ Content

18
3.2 Prevalence rate of multiple myeloma in India
▪ Worldwide the 5 year prevalence of the disease is 2,10,697 or 4.3/1,00,000 population
▪ In India prevalence of multiple myeloma is11,602 or 1.4/1,00,000 population. In India it accounts for around 5,900 deaths every year8 .
The USA SEER data shows that the Age Adjusted Death Rate was 3.4/1,00,000 population
▪ The disease is slightly more prevalent in males with an M:F ratio of 1.2:1 and 1.1:1 worldwide. In India it is 1.3:1. But other single
institution studies from India showed a higher M:F ratio of 2.2:1
▪ Content
▪ Content

19
4. Market Segmentation

20
Snapshot of Multiple myeloma market segmentation
Market Segmentation
By Treatment type
By disease type
Stem Cell
Transplant
Radiation
Therapy
Smouldering
multiple myeloma
Active multiple
myeloma
Medication
By Dosage
forms
Injections
Tablets
Capsule
Others
Others
By Diagnosis
Urine Tests
Bone Marrow
Biopsy
Blood Tests
Imaging
Tests
By Route of
administration
Parenteral
Oral
Others
End-Users
Specialty
Clinics
Hospitals
Homecare
Others
Distribution
Channel
Retail
Pharmacy
Hospital
Pharmacy
Online
Pharmacy
Others

21
▪ Smoldering multiple myeloma is an early form of multiple
myeloma, which does not have symptoms and signs of the
disease
▪ Whereas in active multiple myeloma patient has symptoms
and signs of the disease. Patients with symptoms
▪ Both the segments are growing with the higher prevalence of
the multiple myeloma
Sample
4.1 Market Segmentation: By disease type
India Multiple Myeloma by disease type 2022
Smouldering multiple myeloma Active multiple myeloma
Key Insights

4.2 Market Segmentation: By Treatment type
Medication Radiation Therapy
Stem Cell Transplant Others
Sample
India Multiple Myeloma Market Share by treatment type 2022
▪ The industry with the highest revenue share was headed by the
chemotherapy and other medications segment
▪ Oncologists are turning more and more to chemotherapy to treat
multiple myeloma due to the lack of options and the limits of
surgical techniques
▪ Stem cell transplant and radiation therapies include the first-line
therapy for multiple myeloma
▪ However, the associated demerits including complications in stem
cell transplant procedures and limited applications of radiation
methods are driving the oncologists preference for multi-therapy
regimens, which include a combination of chemotherapy, radiation,
and other supportive treatments based on patient response and
symptoms
Key Insights

23
Blood Tests Bone Marrow Biopsy
Urine Tests Imaging Centres
▪ Blood test are widely used to diagnose the multiple myeloma
as it shows complete blood count (CBC) which indicates
levels of red cells, white cells, and platelets in the blood
▪ If there are too many myeloma cells in the bone marrow,
some of these blood cell levels can be low. The most
common finding is a low red blood cell count
▪ Hence this segment is anticipated to grow at higher CAGR
4.3 Market Segmentation: By Diagnosis
India Multiple Myeloma Market Share by diagnosis 2022
Sample
Key Insights

24
Capsules Tablets Injections Others
India Multiple Myeloma Market Share by dosage forms
2022
4.4 Market Segmentation: By Dosage forms
▪ Based on dosage forms the market is segmented into the
market is segmented into capsules, tablets, injections and
others
▪ Content
▪ Content
Key Insights

25
Oral Parenteral Others
India Multiple Myeloma Market Share route of administration
2022
4.5 Market Segmentation: By Route of administration
▪ The oral segment acquired the major share of the multiple
myeloma, owing to abundant availability of medications,
which are available as oral drugs in the market.
▪ Conversely, the parenteral segment is expected to grow at
the fastest CAGR during the forecast period.
Key Insights

26
Hospitals Specialty Clinics
Homecare Others
▪ The India multiple myeloma Market is segmented into
hospitals, specialty clinics, home care and others by the
Distribution Channels
▪ Hospitals remain the primary point of access for healthcare
services
India Multiple Myeloma Market Share by end-users
2022
4.6 Market Segmentation: By End-Users
Key Insights

27
Hospital Pharmacy Retail Pharmacy
Online Pharmacy Others
India Multiple Myeloma Market Share by distribution channel
2022
4.7 Market Segmentation: By Distribution Channel
▪ In terms of distribution channel, the segmentation of the market
is hospital pharmacy, retail pharmacies, online pharmacies and
others
▪ The key reasons for the dominance of this segment is that the
drugs used in treatment can regularly prescribed and
administered in hospital settings
▪ Although Revlimid is present, there are relatively fewer oral
medicines utilized in treatment, which limits retail pharmacies
segment growth over the projected period
▪ As a result, the retail pharmacies segment is anticipated to
develop at a lower CAGR. Due to the comfort and ease with
which patients can fill their prescriptions, the online pharmacy
market is predicted to grow more rapidly
Sample
Key Insights

28
5. Major Products Market Share

5.1 Market Analysis, Insights and Forecast- By Major Brands
Key Insights
India Multiple Myeloma Market Analysis for Major Brands
2022
Top 5 Brands in Indian Multiple Myeloma
market
Sample
Brand 1 Brand 2 Brand 3 Brand 4 Brand 5

6. Competitive Landscape

6.1 Competitive Landscape: Key Players Revenue
(Current and Forecast)
Major Market Revenue of Top Companies in the Multiple myeloma Market ($Mn)
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Zydus
Pharmaceuticals
$xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Dr. Reddy's
Laboratories
Ciplamed $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Sun Pharma $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Biocon Biologics
India Limited

Competitive Landscape: Key Players Market Share and growth
India Multiple Myeloma Major Players
0 1 2 3 4 5
Biocon Biologics India Limited
Sun Pharma
Ciplamed
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Growth Share Revenue

7. Key Company Profiles

7.1 Zydus Pharmaceuticals
Company Name: Zydus Pharmaceuticals
Year of Establishment: 1952
Headquarter: Ahmedabad, Gujarat, India
Total Revenue: INR15,139 crore (Total)
Website: www.zyduslife.com
Company at a Glance
Company Overview
Sample

Zydus Pharmaceuticals (continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

7.2 Dr. Reddy's Laboratories
Company Name: Dr. Reddy's Laboratories
Headquarter: Hyderabad; Telangana, India
Total Revenue: INR ₹17,460 crore
Website: www.drreddys.com
Company at a Glance
Company Overview
Sample

Dr. Reddy's Laboratories (continued)
Sample
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

7.3 Ciplamed
Company Name: Ciplamed
Headquarter: Mumbai, Maharashtra, India
Website: https://www.cpsi.com/
Sample
Company at a Glance
Company Overview

Ciplamed (continued)
Sample
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

7.4 Sun Pharma
Company Name: Sun Pharma
Headquarter: Mumbai, India
Website: sunpharma.com
Company at a Glance
Company Overview
Sample

Sun Pharma (continued)
Sample
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

7.5 Biocon Biologics India Limited
Company Name: Biocon Biologics India Limited
Headquarter: Bangalore, Karnataka, India
Website: www.biocon.com
Total Revenue: INR ₹8,396.70 crore
Company at a Glance
Company Overview
Sample

Biocon Biologics India Limited (continued)
Sample
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

8. Healthcare Policy and Regulatory Landscape

▪ Ayushman Bharat scheme covers cancer treatment including multiple myeloma, The treatment for this disease needs to undergo a
treatment plan and some approvals like a ‘tumor board concept’ to decide the best patient management
▪ It also requires mandatory approval for clinical treatment for cancer care, as it involves a multi model approach requiring coverage
for chemotherapy, surgeries and radiotherapy and another supported care for best patient care and management
▪ Star Health and Allied Insurance (SHAI) has introduced what it calls an industry-first health insurance cover for people already
diagnosed with cancer. There are other private insurance companies that covered multiple myeloma in the policy
▪ Content
▪ Content
8.1 Policy changes and Reimbursement scenario
Sample

9. Factors Driving Future Growth

9.1 Future Opportunities
▪ Increase in the number of research and development activities
• An rise in research and development efforts is driving the expansion of the multiple myeloma market. This will present
advantageous chances for the expansion of the multiple myeloma market.Along with this, an increase in medication releases
and approvals will speed up the market's expansion
• Monoclonal antibodies (mAbs), such as Empliciti and Darzalex, will present a significant growth opportunity for the market
because they will not only give patients with multiple myeloma a new therapeutic option, but also increase the interval
between relapses, extending the duration of Revlimid and Velcade therapies
• During the projected period, increased investments in the creation of cutting-edge technologies and an increase in the number
of new markets will also present favourable chances for the expansion of the multiple myeloma market
• Content
Sample

10. Strategic Recommendations

Strategic Recommendations
The growth amongst different segments will help you analyze meagre growth segments in the industries and provide the users
with a valuable market overview and market insights to help them make strategic decisions for identifying core market
applications
Content
Content
Content

51 A Sample Report on Report Title I Confidential
Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Primary
Research
Secondary
Research
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Data Collection
Market Data Analysis
& Statistical Model
Interpretation &
Presentation

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2021
2022-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (5 working days) with
purchase. We will provide you with data that is
currently not a part of our scope as a part of
customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

The report is prepared
using a proven
methodology and insightful
research
Reliable
The data is prepared by a
team of highly qualified &
experienced research
analysts & vetted by our
local associates
Expert-verified
Allowing you to confidently
make smarter business and
strategic decisions
Real
Covers everything you
would need to know about
the market including
market size, competitive
analysis & much more
Comprehensive
You do not have to be a
market expert to
understand what really is
happening on the market
and how it works
Easy to read
What kind of Data is Presented
in this Report?
This report presents data, which is:
www.insights10.com

www.insights10.com
A large database of over 30,000 syndicated market
research reports in pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Lifesciences Market
Research Reports you
can trust

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get Insights to take
informed Business
Decisions
www.insights10.com

Market Research Reports
across various domains of healthcare
Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices

Our
Services
1
2
3
4
5
6
10
9
8
7
Market Research Reports
Customized Reports
Primary Research
Database Services
Full-Time Engagement
Conference Coverage
Competitive Intelligence
Strategic Research Projects Regulatory Compliance
Report Subscription Services

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis
www.insights10.com

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players
www.insights10.com

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Mukesh is an engineering graduate
with an MBA in Marketing. He is a
seasoned healthcare market
research & marketing professional
with a progressive experience of over
20 years in Life Sciences, Pharma
and Medical Device sectors. With an
in-depth understanding of primary
research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare
& completed several research
projects across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Dhruv Joshi is an engineer and has done
Masters in Hospital Administration with
over 4 years of experience in the
healthcare and life science industry. He
has gained proficiency in market
research, market assessment, and
developing insights from it. He has
worked on various consulting projects
across different geographies including
Asia, Europe, US, MENA. He has been
aligned in working for sector reports of
various geographies along with market
sizing and forecasting.
Dr. Purav Gandhi
Founder & CEO
Mukesh Nayak
Head - Marketing
Ritu Baliya
Engagement Manager
Dhruv Joshi
Consultant
Project Leadership Team

7 years of experience working with leading organizations in pharma, MedTech
and healthcare domain. Some of our recent clients are mentioned below
… and many more

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.

India Multiple Myeloma Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to India Multiple Myeloma Market Analysis Sample Report

Similar to India Multiple Myeloma Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

India Multiple Myeloma Market Analysis Sample Report